Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Treatments: Iloperidone; Risperidone

Criteria

Inclusion Criteria:

• men and women aged 18 to 65 years with schizophrenia;

• PANSS total score of at least 70 at screening and baseline;

• at least 2 more than 4 points in 7 of PANSS-P;

• informed consent.

Exclusion Criteria:

• allergy with iloperidone or risperidone;

• psychotic symptoms failing to improve after sufficient exposure to 2 antipsychotic treatment;

• any other primary Axis 1 psychiatric diagnosis;

• a history of alcohol or drug dependence in recent 1 year;

• at imminent risk of harm to self or others;

• systolic blood pressure≤90mmHg。